Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MARX Biotech CoROCO:7731 6 EPS without NRI is NT$0.08 as of Dec. 2025. GuruFocus rates ROCO:7731 with a GF Score™ of 6/100. The stock has 5 warning signs investors should review. Among 508 Healthcare Providers & Services companies, MARX Biotech Co ranks better than 95.87% on this metric.
MARX Biotech Co's earnings per share without non-recurring items for the
six
months ended in Dec. 2025 was NT$0.17.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.08.
During the past 3 years, the average earnings per share (NRI) Growth Rate was 91.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for MARX Biotech Co's EPS without NRI or its related term are showing as below:
ROCO:7731'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 91.3 Med: 91.3 Max: 91.3
Current: 91.3
During the past 6 years, MARX Biotech Co's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 91.30% per year. The lowest was 91.30% per year. And the median was 91.30% per year.
ROCO:7731's 3-Year EPS without NRI Growth Rate is ranked better than 95.87% of 508
companies
in the Healthcare Providers & Services industry
Industry Median: 11.3
vs ROCO:7731: 91.30
MARX Biotech Co's EPS (Diluted) for the
six
months ended in Dec. 2025 was NT$0.16.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.08.
MARX Biotech Co's EPS (Basic) for the
six
months ended in Dec. 2025 was NT$0.16.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.08.
MARX Biotech Co (ROCO:7731) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
MARX Biotech Co EPS without NRI Related Terms
MARX Biotech Co EPS without NRI Historical Data
* Premium members only.
The historical data trend for MARX Biotech Co's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MARX Biotech Co EPS without NRI Competitor Comparison
For the Pharmaceutical Retailers subindustry, MARX Biotech Co's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MARX Biotech Co PE Ratio without NRI vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, MARX Biotech Co's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where MARX Biotech Co's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$0.08
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MARX Biotech Co (ROCO:7731) has a EPS without NRI of NT$0.08 as of Dec. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on MARX Biotech Co and its competitors. According to the industry distribution chart, MARX Biotech Co ranks #21 out of 508 companies in the Healthcare Providers & Services industry, placing it in the top 4.1%.
Is MARX Biotech Co's EPS without NRI too high?
MARX Biotech Co's current EPS without NRI is NT$0.08. Based on the distribution chart, MARX Biotech Co ranks #21 out of 508 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, MARX Biotech Co has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does MARX Biotech Co's EPS without NRI compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, MARX Biotech Co ranks #21 out of 508 companies for EPS without NRI. This places MARX Biotech Co in the top 4% of its industry — outperforming the majority of peers. The industry median EPS without NRI is 11.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Healthcare Providers & Services company?
The median EPS without NRI among Healthcare Providers & Services companies is 11.30, based on 508 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on MARX Biotech Co and its competitors. For the Healthcare Providers & Services industry, the median EPS without NRI is 11.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MARX Biotech Co's current EPS without NRI is NT$0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MARX Biotech Co stock overvalued right now?
MARX Biotech Co (ROCO:7731) has a current EPS without NRI of NT$0.08. The current EPS without NRI is NT$0.08. MARX Biotech Co's overall GF Score™ is 6/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For MARX Biotech Co (ROCO:7731), the current EPS without NRI is NT$0.08 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MARX Biotech Co Ltd is a retail company which has developed an O2O and OMO full-channel layout in the online Internet platform and cosmeceutical retail market, and has successfully established itself in the market and Build trust and operational growth on the channel side. It has has established more than three thousand large and small cosmeceutical pharmacies in Taiwan, including: Dashu Pharmacy, Dingding Pharmacy, Cosmed, Watsons, Spring Pharmacy, New Gaoqiao Pharmacy, Anlier Pharmacies, etc.
6GF Score
Get the complete analysis for ROCO:7731
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7731 has been successfully added to your 
